Trial · NCT01551758
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Annual Rate of Moderate or Severe COPD Exacerbations | Up to 54 weeks | Primary Efficacy Analysis Population. | Exacerbations per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study | Up to 58 weeks | The Intent-to-Treat (ITT) Population: Defined as all participants who were randomised and received at least one prescription of study medication | Participants | NUMBER |
| SECONDARY | Mean Number of Serious Adverse Events of Pneumonia During the Study | Up to 58 weeks | ITT Population. | Mean Number of SAE | LEAST_SQUARES_MEAN |
| SECONDARY | Time to the First Serious Adverse Event of Pneumonia Occuring in a Year | Up to 52 weeks | ITT Population | Participants | NUMBER |
| SECONDARY | Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean | Up to 54 weeks | ITT Population. | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean | Up to 54 weeks | ITT Population. | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of All Secondary Care Contacts Expressed Using Least Square Mean | Up to 54 weeks | ITT Population. | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of All Primary Care Contacts Expressed Using Least Square Mean | Up to 54 weeks | ITT Population. | Contacts per participant per year | LEAST_SQUARES_MEAN |
| SECONDARY | Time to an Event of Discontinuation of Initial Therapy Occurring in a Year | Up to 364 days | ITT Population | Participants | NUMBER |
| SECONDARY | Time to the Addition of a Further COPD Controller Medication Occurring in a Year | Up to 364 days | ITT Population | Participants | NUMBER |
| SECONDARY | Time to First Moderate/Severe Exacerbations Occurring in a Year | Up to 364 days | ITT Population | Participants | NUMBER |
| SECONDARY | Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year | Up to 364 days | ITT Population | Participants | NUMBER |
| SECONDARY | Time to First Severe Exacerbations Occurring in a Year | Up to 364 days | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With Fatal Serious Adverse Events of Pneumonia | Upto 58 weeks | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With Non-serious Adverse Drug Reactions (ADR) | Up to 54 weeks | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With Serious Adverse Events | Up to 56 weeks | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With Serious Adverse Drug Reactions | Upto 12 months | ITT Population | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01551758/outcomes